Comparison of thalidomide versus apatinib for prevention of camrelizumab-induced reactive cutaneous capillary endothelial proliferation: a retrospective study

Volume 8, Issue 2, April 2023     |     PP. 141-152      |     PDF (190 K)    |     Pub. Date: April 9, 2023
DOI: 10.54647/cm321042    89 Downloads     4004 Views  

Author(s)

Geng Song, Department of oncology, The second affiliated hospital of Anhui Medical University, Hefei 230601, China
Fei-Fei Zhang, Department of oncology, The second affiliated hospital of Anhui Medical University, Hefei 230601, China
Huai-Dong Cheng, Department of oncology, The second affiliated hospital of Anhui Medical University, Hefei 230601, China

Abstract
Objectives: We retrospectively evaluated the effect of thalidomide and apatinib in prevention of camrelizumab-induced reactive cutaneous capillary endothelial proliferation (RCCEP).
Methods: In this study, the clinical data of enrolled patients who received either camrelizumab plus thalidomide therapy (thalidomide group) or camrelizumab plus apatinib therapy (apatinib group) were retrospectively analyzed. The incidences of RCCEP and the adverse events of thalidomide and apatinib were analyzed.
Results: Between June 2017 and October 2022, 30 patients were enrolled. Although the incidence of RCCEP in thalidomide group (4/15, 26.7%) was lower than that in apatinib group (6/15, 40%), the significance threshold was not met (p=0.45). The adverse events of thalidomide included fatigue, constipation, oedema and rash which were mild in severity and manageable, and no treatment-associated interruptions were observed.
Conclusions: Compared with apatinib, thalidomide exhibits a trend towards better prevention of RCCEP with an acceptable tolerance in patients receiving camrelizumab treatment.

Keywords
thalidomide, apatinib, camrelizumab, reactive cutaneous capillary endothelial proliferation

Cite this paper
Geng Song, Fei-Fei Zhang, Huai-Dong Cheng, Comparison of thalidomide versus apatinib for prevention of camrelizumab-induced reactive cutaneous capillary endothelial proliferation: a retrospective study , SCIREA Journal of Clinical Medicine. Volume 8, Issue 2, April 2023 | PP. 141-152. 10.54647/cm321042

References

[ 1 ] Naimi A, Mohammed RN, Raji A, Chupradit S, Yumashev AV, Suksatan W, et al. Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons. Cell Commun Signal, 2022; 20(1):44-74. doi: 10.1186/s12964-022-00854-y.
[ 2 ] Perdigoto AL, Kluger H, Herold KC. Adverse events induced by immune checkpoint inhibitors. Curr Opin Immunol, 2021; 69:29-38. doi: 10.1016/j.coi.2021.02.002.
[ 3 ] Geisler AN, Phillips GS, Barrios DM, Wu J, Leung DYM, Moy AP, et al. Immune checkpoint inhibitor-related dermatologic adverse events. J Am Acad Dermatol, 2020; 83(5):1255-1268. doi: 10.1016/j.jaad.2020.03.132.
[ 4 ] Jing H, Binghe X, Hongnan M, Weilong Z, Xuelian C, Dawei W, et al. Safety, activity, and biomarkers of SHR-1210, an anti-PD-1 antibody, for patients with advanced esophageal carcinoma. Clin Cancer Res, 2018; 24(6):1296-1304. doi: 10.1158/1078-0432.CCR-17-2439.
[ 5 ] Fang W, Yang Y, Ma Y, Hong S, Lin L, He X, et al. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials. Lancet Oncol, 2018; 19(10):1338-1350. doi: 10.1016/S1470-2045(18)30495-9.
[ 6 ] Wenhong L, Zhigang W, Xia Y, Guanghui H, Xiaoying H, Yang N, et al. Salvage therapy of reactive capillary hemangiomas: apatinib alleviates the unique adverse events induced by camrelizumab in non-small cell lung cancer. J Cancer Res Ther, 2019; 15(7):1624-1628. doi: 10.4103/jcrt.JCRT_997_19.
[ 7 ] Shao F, Zhang H, Yang X, Luo X, Liu J. Adverse events and management of apatinib in patients with advanced or metastatic cancers: a review. Neoplasma, 2020; 67(4):715-723. doi: 10.4149/neo_2020_190801N701.
[ 8 ] Song G, Zhang FF, Cheng HD. Thalidomide for prevention of camrelizumab-induced reactive cutaneous capillary endothelial proliferation. Australas J Dermatol, 2022; 63(2):217-221. doi: 10.1111/ajd.13812.
[ 9 ] Zhao J, Su CX. Comments on CSCO management guideline of toxicities from immunecheckpoint inhibitors: comparing with NCCN guideline. J Pract Oncol, 2020; 35(1):11-15. doi: 10.13267/j. cnki. syzlzz. 2020.01.002.
[ 10 ] Chen AP, Setser A, Anadkat MJ, et al. Grading dermatologic adverse events of cancer treatments: the Common Terminology Criteria for Adverse Events Version 4.0. J Am Acad Dermatol, 2012; 67(5):1025-1039. doi: 10.1016/j.jaad.2012.02.010.
[ 11 ] Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol, 2018; 4(12):1721-1728. doi: 10.1001/jamaoncol.2018.3923.
[ 12 ] Belum VR, Benhuri B, Postow MA, Hellmann MD, Lesokhin AM, Segal NH, et al. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer, 2016; 60:12-25. doi: 10.1016/j.ejca.2016.02.010.
[ 13 ] Xu J, Zhang Y, Jia R, Yue C, Chang L, Liu R, et al. Anti-PD-1 antibody SHR-1210 combined with apatinib for advanced hepatocellular carcinoma, gastric, or esophagogastric junction cancer: an open-label, dose escalation and expansion study. Clin Cancer Res, 2019; 25(2):515-523. doi: 10.1158/1078-0432.CCR-18-2484.
[ 14 ] Bertolini F, Mingrone W, Alietti A, Ferrucci PF, Cocorocchio E, Peccatori F, et al. Thalidomide in multiple myeloma, myelodysplastic syndromes and histiocytosis. Analysis of clinical results and of surrogate angiogenesis markers. Ann Oncol, 2001; 12(7):987-990. doi: 10.1023/a:1011141009812.
[ 15 ] Wang D, Yang X, Long J, Lin J, Mao J, Xie F, et al. The efficacy and safety of apatinib plus camrelizumab in patients with previously treated advanced biliary tract cancer: a prospective clinical study. Front Oncol, 2021; 11:646979. doi: 10.3389/fonc.2021.646979.
[ 16 ] Jianming X, Jie Sh, Shanzhi G, Yun Zh, Lihua W, Jian W, et al. Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): a nonrandomized, open-label, phase II trial. Clin Cancer Res, 2021; 27(4):1003-1011. doi: 10.1158/1078-0432.CCR-20-2571.
[ 17 ] Liu J, Liu Q, Li Y, Li Q, Su F, Yao H, et al. Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial. J Immunother Cancer, 2020; 8(1):e000696. doi: 10.1136/jitc-2020-000696.
[ 18 ] Zhi P, Jia W, Feng W, Jieer Y, Yanhong D, Kangsheng G, et al. Camrelizumab combined with chemotherapy followed by camrelizumab plus apatinib as first-line therapy for advanced gastric or gastroesophageal junction adenocarcinoma. Clin Cancer Res, 2021; 27(11):3069-3078. doi: 10.1158/1078-0432.CCR-20-4691.
[ 19 ] Xie L, Xu J, Sun X, Guo W, Gu J, Liu K, et al. Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial. J Immunother Cancer, 2020; 8(1):e000798. doi: 10.1136/jitc-2020-000798.
[ 20 ] Feng-E J, Hui-Juan Zh, Cai-Yan Y, Ai-Na L. Efficacy and safety of regorafenib or fruquintinib plus camrelizumab in patients with microsatellite stable and/or proficient mismatch repair metastatic colorectal cancer: an observational pilot study. Neoplasma, 2021; 68(4):861-866. doi: 10.4149/neo_2021_201228N1415.
[ 21 ] Chen X, Ma L, Wang X, Mo H, Wu D, Lan B, et al. Reactive capillary hemangiomas: a novel dermatologic toxicity following anti-PD-1 treatment with SHR-1210. Cancer Biol Med, 2019; 16(1):173-181. doi: 10.20892/j.issn.2095-3941.2018.0172.
[ 22 ] Wang F, Qin S, Sun X, Ren Z, Meng Z, Chen Z, et al. Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial. J Hematol Oncol, 2020; 13(1):47. doi: 10.1186/s13045-020-00886-2.
[ 23 ] Jiang F, Zhang HJ, Yu CY, Liu A. Efficacy and safety of regorafenib or fruquintinib plus camrelizumab in patients with microsatellite stable and/or proficient mismatch repair metastatic colorectal cancer: an observational pilot study. Neoplasma, 2021; 68(4):861-866. doi: 10.4149/neo_2021_201228N1415.
[ 24 ] Yunpeng Y, Ting ZH, Xiaozhong CH, Jingao L, Jianji P, Xiaohui H, et al. Efficacy, safety, and biomarker analysis of camrelizumab in previously treated recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN study). J Immunother Cancer, 2021; 9(12):e003790. doi: 10.1136/jitc-2021-003790.